Cargando…

Dasiglucagon, a next‐generation ready‐to‐use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial

BACKGROUND: Dasiglucagon, a next‐generation, ready‐to‐use aqueous glucagon analog formulation, has been developed to treat severe hypoglycemia in individuals with diabetes. OBJECTIVE: The aim of this trial was to evaluate the safety and efficacy of dasiglucagon in pediatric individuals with type 1 d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Battelino, Tadej, Tehranchi, Ramin, Bailey, Timothy, Dovc, Klemen, Melgaard, Anita, Yager Stone, Jenine, Woerner, Stephanie, von dem Berge, Thekla, DiMeglio, Linda, Danne, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons A/S 2021
Materias:	Clinical Care and Technology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361970/ https://www.ncbi.nlm.nih.gov/pubmed/33934456 http://dx.doi.org/10.1111/pedi.13220

Ejemplares similares

Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial
por: Pieber, Thomas R., et al.
Publicado: (2021)

A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia
por: Bailey, Naila Celeste, et al.
Publicado: (2022)

Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study
por: Tehranchi, Ramin, et al.
Publicado: (2022)

Time in range centered diabetes care
por: Dovc, Klemen, et al.
Publicado: (2021)

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
por: Hropot, Tim, et al.
Publicado: (2023)

Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia
por: Schaumleffel, Carol
Publicado: (2023)

Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model
por: Hinahara, Jordan, et al.
Publicado: (2022)

Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis
por: Maji, Shampa, et al.
Publicado: (2023)

Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons
por: Pontiroli, Antonio E., et al.
Publicado: (2022)

Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial
por: Dovc, Klemen, et al.
Publicado: (2017)

Validation of the Lifetime Incidence of Traumatic Events (LITE-S/P) Questionnaires in Children and Adolescents in Slovenia
por: Uršič, Katarina, et al.
Publicado: (2021)

Patient reported outcome measures in children and adolescents with type 1 diabetes using advanced hybrid closed loop insulin delivery
por: Gianini, Ana, et al.
Publicado: (2022)

Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia
por: Giménez, Marga, et al.
Publicado: (2023)

A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia()
por: Chabenne, Joseph, et al.
Publicado: (2014)

MON-LB115 Ready-To-Use Glucagon for the Prevention of Exercise-Induced Hypoglycemia in a Clinical Research Setting
por: Aronson, Ronnie, et al.
Publicado: (2020)

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
por: Rickels, Michael R., et al.
Publicado: (2016)

Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes
por: Battelino, Tadej, et al.
Publicado: (2011)

Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes
por: Aronson, Ronnie, et al.
Publicado: (2023)

Contribution of Retrotransposons to the Pathogenesis of Type 1 Diabetes and Challenges in Analysis Methods
por: Štangar, Anja, et al.
Publicado: (2023)

Screening of lipids and kidney function in children and adolescents with Type 1 Diabetes: does age matter?
por: Catamo, Eulalia, et al.
Publicado: (2023)

Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia
por: Pontiroli, Antonio E., et al.
Publicado: (2019)

The association between anti‐insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast‐acting insulin aspart in children and adolescents with type 1 diabetes
por: Biester, Torben, et al.
Publicado: (2020)

Acute Hyperglycemia and Spatial Working Memory in Adolescents With Type 1 Diabetes
por: Šuput Omladič, Jasna, et al.
Publicado: (2020)

Carer's Attachment Anxiety, Stressful Life-Events and the Risk of Childhood-Onset Type 1 Diabetes
por: Turin, Anja, et al.
Publicado: (2021)

SAT107 Assessing Continuous Glucose Monitor Alarm Use By Families Of Children With Diabetes
por: Ochs, Victoria S, et al.
Publicado: (2023)

Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies
por: Christiansen, Mark P, et al.
Publicado: (2021)

Role of HNFA1 Gene Variants in Pancreatic Beta Cells Function and Glycaemic Control in Young Individuals with Type 1 Diabetes
por: Robino, Antonietta, et al.
Publicado: (2023)

Heterozygous NPR2 Variants in Idiopathic Short Stature
por: Stavber, Lana, et al.
Publicado: (2022)

Altered Taste Function in Young Individuals With Type 1 Diabetes
por: Catamo, Eulalia, et al.
Publicado: (2022)

ISPAD Clinical Practice Consensus Guidelines 2022: Assessment and management of hypoglycemia in children and adolescents with diabetes
por: Abraham, Mary B., et al.
Publicado: (2022)

Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
por: Kedia, Nitil
Publicado: (2011)

Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes
por: Siafarikas, Aris, et al.
Publicado: (2012)

A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia
por: Lobato, Carolina B., et al.
Publicado: (2020)

Hypoglycemia masquerading as acute psychosis in young age
por: Klemen, P, et al.
Publicado: (2000)

Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus
por: Hövelmann, Ulrike, et al.
Publicado: (2018)

Extracellular Vesicles Derived Human-miRNAs Modulate the Immune System in Type 1 Diabetes
por: Tesovnik, Tine, et al.
Publicado: (2020)

Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics
por: Pozzilli, Paolo, et al.
Publicado: (2015)

Skin manifestations in rare types of diabetes and other endocrine conditions
por: Reschke, Felix, et al.
Publicado: (2023)

Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
por: Sherr, Jennifer L., et al.
Publicado: (2016)

Mitochondrial GTP Insensitivity Contributes to Hypoglycemia in Hyperinsulinemia Hyperammonemia by Inhibiting Glucagon Release
por: Kibbey, Richard G., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7p6o868qnkr464241brdfo041j